Published in
Oxford University Press (OUP), Clinical Infectious Diseases, 8(45), p. 1019-1024
DOI: 10.1086/521912
Links
Tools
Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Journal article published in 2007 by
F. S. de Fontbrune,
M. Robin,
R. Porcher 
,
C. Scieux,
R. P. de Latour,
C. Ferry,
V. Rocha,
K. Boudjedir,
A. Devergie,
A. Bergeron ,
E. Gluckman,
E. Azoulay,
J. Lapalu,
G. Socie,
P. Ribaud
,
C. Scieux,
R. P. de Latour,
C. Ferry,
V. Rocha,
K. Boudjedir,
A. Devergie,
A. Bergeron ,
E. Gluckman,
E. Azoulay,
J. Lapalu,
G. Socie,
P. Ribaud
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.